This page was translated automatically from Turkish. Read the original

This page is an AI-assisted Turkish summary of the study presented at the 26th World Congress of Psychiatry. The study belongs to the presenting authors; please refer to the original source when citing it.

SO145

Gut microbiota alterations in major depressive disorder: a systematic review and clinical implications

ALTERATIONS IN GUT MICROBIOTA IN MAJOR DEPRESSIVE DISORDER: A SYSTEMATIC REVIEW AND CLINICAL IMPLICATIONS

Gut microbiota alterations in major depressive disorder are supported by clinical evidence, and the gut–brain axis is emerging as a biologically plausible target for adjunctive therapeutic interventions.

The aim of the study was to evaluate the clinical evidence on the relationship between gut microbiota composition and major depressive disorder (MDD) and to examine the effects of microbiota-targeted interventions on depressive symptoms. PubMed, Embase, and PsycINFO were searched for clinical studies published through January 2025; observational studies and randomized controlled trials (RCTs) were included, while preclinical studies and case reports were excluded. Ten studies met the predefined eligibility criteria. Patients with MDD showed alterations in microbial composition, differences in diversity, and a reduced relative abundance of short-chain fatty acid (SCFA)-producing bacteria, although findings varied across studies. In some samples, inflammatory markers were associated with symptom severity. Randomized trials of probiotic supplementation showed modest but statistically significant improvements in depressive symptoms. Methodological heterogeneity was substantial. The authors state that the available clinical evidence supports an association between gut microbiota alterations and MDD and highlights the relevance of the microbiome to future individualized treatment strategies in psychiatry. The poster does not report a pooled effect size, ratio, or p-value.

All WCP 2026 summaries